Elekta to acquire Nucletron, complementing its product offering with world-leading brachytherapy technology
Stockholm, Sweden, June 21, 2011
Elekta has agreed to acquire Nucletron for EUR 365 million in cash. The acquisition is expected to be accretive to Elekta’s cash earnings within twelve months. The transaction remains subject to regulatory approval and is expected to close in early autumn 2011.
Through this compelling combination Elekta will offer a complete range of radiotherapy planning and delivery technologies, enhancing its combined ability to meet the clinical needs of cancer patients and health care providers throughout the world.
Elekta today announced the signing of a definitive agreement to acquire Nucletron, the world leader in brachytherapy treatment planning and delivery. Nucletron is the global market leader in brachytherapy with 2010 reported revenues of EUR 128 million and EBITDA of EUR 26 million.
Nucletron will add 1,000 new customers to Elekta’s customer base of more than 5,000. The two companies have highly synergistic product and technology portfolios. The combination will lead to enhanced solutions for customers and patients, and will allow the enlarged group to take mutual advantage of Nucletron’s expertise in brachytherapy combined with Elekta’s global presence, particularly in emerging markets.
Under the terms of the agreement, Elekta will pay cash consideration of EUR 365 million to acquire Nucletron on a cash and debt-free basis. The transaction, which has been approved by the Board of Directors of both companies, is subject to regulatory approval and is expected to close in early autumn 2011.
The acquisition is expected to be accretive to Elekta’s cash earnings within twelve months. The transaction will be financed through existing cash on hand and available credit facilities. The proforma business will continue to have a strong financial profile.
“Elekta and Nucletron have a long history of collaboration. Nucletron has a very talented team and the company has created a truly market leading business. The combination creates an excellent opportunity for our patients, customers, employees and shareholders.” said Elekta President and CEO Tomas Puusepp. “The combination with Nucletron enhances Elekta’s product portfolio, offers significant opportunities and extends our geographic reach and distribution capacity.”
“This integrated product portfolio is particularly important, as the combination of brachytherapy and external beam radiation therapy treatments continues to emerge as a leading course of therapy for cancer worldwide,” he added.
“By joining forces with Elekta, Nucletron becomes part of a world leading provider of therapy for many types of cancers. I believe the combination represents a unique opportunity to realize Nucletron’s true potential, gain critical mass and continue to invest in the development of brachytherapy. We look forward to working with our new colleagues”, said Nucletron CEO Jos Lamers.
BofA Merrill Lynch served as Elekta’s exclusive financial advisor on the transaction, and NautaDutilh served as its legal counsel. Jefferies International served as exclusive financial advisor to Nucletron. Allen & Overy served as Nucletron’s legal counsel.